338454-98-1

Basic information

• Product Name: 4-(4-Bromo-2-fluorobenzyl)morpholine
• Synonyms: 4-(4-Bromo-2-fluorobenzyl)morpholine
• CAS NO: 338454-98-1
• Molecular Formula: C₁₁H₁₃BrFNO
• Molecular Weight: 274.1294232
• Product Categories: alkyl bromide|alkyl Fluorine
• Mol File: 338454-98-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /Solid
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-(4-Bromo-2-fluorobenzyl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Bromo-2-fluorobenzyl)morpholine(338454-98-1)
• EPA Substance Registry System: 4-(4-Bromo-2-fluorobenzyl)morpholine(338454-98-1)

Safety Data

• Hazardous Substances Data: 338454-98-1(Hazardous Substances Data)

Usage

General Description

4-(4-Bromo-2-fluorobenzyl)morpholine is a chemical compound that consists of a morpholine ring with a 4-(4-bromo-2-fluorophenyl) group attached to it. 4-(4-Bromo-2-fluorobenzyl)morpholine is commonly used as a building block in the synthesis of various pharmaceutical and agrochemical products. It has been studied for its potential antiviral, antifungal, and antibacterial properties. Additionally, 4-(4-Bromo-2-fluorobenzyl)morpholine has been investigated for its potential use as a ligand in metal-catalyzed reactions and as a precursor in organic synthesis. Overall, this chemical has shown potential applications in the pharmaceutical and chemical industries due to its versatile reactivity and potential biological activity.

Upstream product

• 51436-99-8 2-fluoro-4-bromotoluene 
• 110-91-8 morpholine 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 76283-09-5 4-bromo-2-fluorobenzyl bromide 

Downstream Products

• 1073354-74-1 4-{[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl}morpholine 
• 933986-53-9 (E)-4-(2-fluoro-4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl)benzyl)morpholine 

Relevant articles and documents

TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS

Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy

The antiplasmodial activity, DMPK properties, and efficacy of a series of quinoline-4-carboxamides are described. This series was identified from a phenotypic screen against the blood stage of Plasmodium falciparum (3D7) and displayed moderate potency but with suboptimal physicochemical properties and poor microsomal stability. The screening hit (1, EC50 = 120 nM) was optimized to lead molecules with low nanomolar in vitro potency. Improvement of the pharmacokinetic profile led to several compounds showing excellent oral efficacy in the P. berghei malaria mouse model with ED90 values below 1 mg/kg when dosed orally for 4 days. The favorable potency, selectivity, DMPK properties, and efficacy coupled with a novel mechanism of action, inhibition of translation elongation factor 2 (PfEF2), led to progression of 2 (DDD107498) to preclinical development.

Anti-Malarial Agents

The present invention relates to a novel class of quinolone-4-carboxamide Pf3D7 inhibitors of general formula (I) (Formula (I)) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and in the treatment of malaria in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.